ABUS Arbutus Biopharma Corporation Stock Quote

ABUS [NASD]

Index	-	P/E	-	EPS (ttm)	-0.60	Insider Own	26.89%	Shs Outstand	148.75M	Perf Week	1.20%
Market Cap	374.84M	Forward P/E	-	EPS next Y	-0.60	Insider Trans	0.00%	Shs Float	109.63M	Perf Month	-0.39%
Income	-76.10M	PEG	-	EPS next Q	-0.13	Inst Own	29.60%	Short Float	4.35%	Perf Quarter	9.52%
Sales	33.40M	P/S	11.22	EPS this Y	16.80%	Inst Trans	-0.12%	Short Ratio	4.95	Perf Half Y	-19.94%
Book/sh	1.03	P/B	2.46	EPS next Y	-	ROA	-37.00%	Target Price	6.30	Perf Year	-17.59%
Cash/sh	1.01	P/C	2.50	EPS next 5Y	-	ROE	-66.50%	52W Range	1.93 - 6.50	Perf YTD	-34.96%
Dividend	-	P/FCF	-	EPS past 5Y	35.10%	ROI	-	52W High	-61.08%	Beta	2.25
Dividend %	-	Quick Ratio	5.30	Sales past 5Y	49.10%	Gross Margin	-	52W Low	31.09%	ATR	0.12
Employees	85	Current Ratio	5.30	Sales Q/Q	517.40%	Oper. Margin	-	RSI (14)	52.40	Volatility	3.36% 4.88%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	59.20%	Profit Margin	-	Rel Volume	0.90	Prev Close	2.50
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 04 BMO	Payout	-	Avg Volume	962.82K	Price	2.53
Recom	2.00	SMA20	3.65%	SMA50	-1.76%	SMA200	-15.49%	Volume	867,986	Change	1.20%

Feb-02-22

Upgrade

Jefferies

Hold → Buy

Feb-25-21

Initiated

Jefferies

Hold

Dec-17-20

Initiated

H.C. Wainwright

Buy

$10

Jul-27-20

Resumed

JMP Securities

Mkt Outperform

$10 → $8

Jul-24-20

Downgrade

Robert W. Baird

Outperform → Neutral

May-19-20

Upgrade

Wedbush

Neutral → Outperform

Mar-06-20

Upgrade

Chardan Capital Markets

Neutral → Buy

Feb-20-20

Initiated

Robert W. Baird

Outperform

Feb-05-20

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

$10

Oct-07-19

Reiterated

B. Riley FBR

Buy

$7 → $3

Oct-04-19

Downgrade

Chardan Capital Markets

Buy → Neutral

Oct-16-18

Upgrade

B. Riley FBR

Neutral → Buy

$11.50 → $9

Oct-15-18

Upgrade

Wedbush

Underperform → Neutral

Oct-12-18

Reiterated

Chardan Capital Markets

Buy

$12 → $6.50

Jul-06-18

Downgrade

B. Riley FBR, Inc.

Buy → Neutral

$9 → $9

Mar-19-18

Resumed

Chardan Capital Markets

Buy

$8.25

Mar-19-18

Downgrade

Wedbush

Outperform → Neutral

$9 → $6

Jan-05-18

Initiated

B. Riley FBR, Inc.

Buy

$10

Apr-04-17

Upgrade

Chardan Capital Markets

Neutral → Buy

$3 → $6

Feb-01-17

Reiterated

Wedbush

Outperform

$13 → $10

Aug-10-22 06:26AM	Analysts Just Shipped A Dazzling Upgrade To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Estimates Simply Wall St.
Aug-04-22 07:30PM	Arbutus Biopharma (ABUS) Q2 2022 Earnings Call Transcript Motley Fool
09:05AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM	Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update GlobeNewswire
Jul-21-22 07:30AM	Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update GlobeNewswire
Jul-20-22 04:10PM	Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor GlobeNewswire
Jul-06-22 12:00PM	All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy Zacks
Jun-28-22 03:36PM	This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B Benzinga
Jun-25-22 04:05AM	Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress 2022 and Provides AB-836 Clinical Update GlobeNewswire
Jun-08-22 02:05AM	Arbutus to Present Seven Scientific Posters at EASL International Liver Congress 2022 GlobeNewswire
Jun-06-22 02:45PM	We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth Simply Wall St. -5.19%
07:32AM	Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus GlobeNewswire
07:30AM	Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus GlobeNewswire
Jun-02-22 07:30AM	Arbutus to Participate in June Investor Conferences GlobeNewswire +7.32%
May-26-22 05:05PM	Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-20-22 03:04PM	Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds American City Business Journals
May-17-22 07:30AM	Arbutus to Present at H.C. Wainwright Global Investment Conference GlobeNewswire +6.64%
May-09-22 08:16AM	Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ Benzinga -11.86%
May-07-22 08:05AM	Party Time: Brokers Just Made Major Increases To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Earnings Forecasts Simply Wall St.
May-05-22 02:30PM	Arbutus Biopharma (ABUS) Q1 2022 Earnings Call Transcript Motley Fool
08:55AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:30AM	Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update GlobeNewswire
May-04-22 06:55PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates Zacks
May-02-22 07:58AM	Arbutus Biopharma (NASDAQ:ABUS) investors are sitting on a loss of 33% if they invested a year ago Simply Wall St.
Apr-21-22 07:30AM	Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update GlobeNewswire
Mar-24-22 02:51PM	Pfizer's Canadian partner sues Arbutus Biopharma in Covid-19 vaccine patent dispute American City Business Journals
Mar-18-22 01:00PM	UPDATE 1-Canadian Pfizer partner sues to head off patent lawsuit over COVID-19 vaccine Reuters
11:07AM	Canadian Pfizer partner sues to head off patent lawsuit over COVID-19 vaccine Reuters
11:04AM	Canadian Pfizer partner sues to head off patent lawsuit over COVID-19 vaccine Reuters
Mar-09-22 08:00AM	This 1 New Threat Could Punish Moderna Stock Motley Fool +10.76%
Mar-08-22 04:13AM	New Forecasts: Here's What Analysts Think The Future Holds For Arbutus Biopharma Corporation (NASDAQ:ABUS) Simply Wall St.
Mar-05-22 06:48AM	What Type Of Shareholders Own The Most Number of Arbutus Biopharma Corporation (NASDAQ:ABUS) Shares? Simply Wall St.
Mar-03-22 05:30PM	Arbutus Biopharma (ABUS) Q4 2021 Earnings Call Transcript Motley Fool
10:05AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:30AM	Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update GlobeNewswire
Feb-28-22 11:22AM	Bucks County biopharm firm files lawsuit against Moderna over Covid-19 vaccine American City Business Journals
09:24AM	Arbutus, Genevant sue Moderna, citing patent infringement MarketWatch
06:34AM	Arbutus files patent infringement lawsuit against Moderna related to COVID shot Reuters
06:32AM	UPDATE 4-Arbutus files patent infringement lawsuit against Moderna related to COVID shot Reuters
06:02AM	Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna GlobeNewswire
06:01AM	Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna GlobeNewswire
Feb-25-22 10:14AM	Aerie (AERI) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
Feb-24-22 05:49PM	Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil Zacks +7.87%
Feb-22-22 05:25PM	Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates Zacks +6.27%
Feb-17-22 07:30AM	Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update GlobeNewswire -5.03%
Feb-08-22 05:15PM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates Zacks
Feb-05-22 08:55AM	What's the Outlook for Arbutus Biopharma? Motley Fool
Jan-27-22 09:38AM	First Quadrant L P Buys Innoviva Inc, NOW Inc, General Electric Co, Sells , Brookfield Asset ... GuruFocus.com -9.70%
Jan-24-22 07:30AM	Arbutus Announces 2022 Corporate Objectives and Provides Financial Update GlobeNewswire
Jan-05-22 08:32AM	Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't? Zacks -5.36%
Jan-04-22 07:30AM	Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference GlobeNewswire -6.28%
Dec-23-21 12:38PM	Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ... GuruFocus.com
Dec-14-21 07:30AM	Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection GlobeNewswire -5.05%
Dec-13-21 10:52AM	Arbutus enters into $300M deal for experimental hepatitis B drug with Chinese pharma firm American City Business Journals +5.31%
07:30AM	Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan GlobeNewswire
Dec-12-21 06:14AM	Here's Why We're Not Too Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation Simply Wall St.
Dec-09-21 01:39PM	Keep on Buying Arbutus Stock Before It Jumps 80%, Says Analyst TipRanks
Dec-08-21 07:47AM	Anixa (ANIX) COVID Compounds Prove Effective Against Omicron Zacks
Dec-07-21 07:30AM	Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement GlobeNewswire +6.74%
Dec-03-21 11:34AM	Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options Zacks
Dec-02-21 01:08PM	Arbutus: Still Plenty of Upside Left Following Favorable Court Decision TipRanks -6.51%
07:25AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday InvestorPlace
Dec-01-21 06:22PM	Why Moderna Stock Plunged Today Motley Fool +44.06%
02:01PM	ABUS Stock Alert: The Moderna News That Has Arbutus Biopharma Shares Rocketing Today InvestorPlace
12:20PM	Why Arbutus Biopharma Is Rocketing Higher Today Motley Fool
11:58AM	Preliminary Data Shows that Arbutus Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity GlobeNewswire
07:22AM	Arbutus Shares Rise Moderna's Fall After Patent Appeal Denied Investing.com
Nov-11-21 07:30AM	Arbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors GlobeNewswire
Nov-10-21 04:30PM	Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting® GlobeNewswire
07:30AM	Arbutus to Participate at Jefferies London Healthcare Conference GlobeNewswire
Nov-04-21 11:03PM	Arbutus Biopharma (ABUS) Q3 2021 Earnings Call Transcript Motley Fool
08:55AM	Arbutus Biopharma (ABUS) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:30AM	Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Nov-01-21 04:05PM	Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021 GlobeNewswire
Oct-28-21 03:05PM	Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-21-21 07:30AM	Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update GlobeNewswire
Oct-13-21 06:27AM	Arbutus Biopharma (NASDAQ:ABUS) shareholders have earned a 7.3% CAGR over the last five years Simply Wall St.
Oct-07-21 11:33AM	Why Moderna Stock Is Rebounding Today Motley Fool
08:30AM	Thinking about buying stock in Tata Motors, New Fortress Energy, Arbutus Biopharma, US Well Services, or Progenity? PR Newswire
Sep-28-21 07:30AM	Arbutus to Participate in October Investor Conferences GlobeNewswire -6.49%
Sep-27-21 08:32AM	Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't? Zacks
Sep-21-21 07:30AM	Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations GlobeNewswire
Sep-07-21 08:00AM	Arbutus to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-23-21 08:26AM	Is the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock? Zacks +6.51%
Aug-14-21 03:09AM	Here's What Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shareholder Ownership Structure Looks Like Simply Wall St.
Aug-07-21 10:30AM	Arbutus Biopharma (ABUS) Q2 2021 Earnings Call Transcript Motley Fool
Aug-05-21 08:55AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates Zacks +10.14%
07:30AM	Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Aug-03-21 08:00AM	Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
Jul-29-21 08:00AM	Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update GlobeNewswire
Jul-07-21 07:00AM	Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent GlobeNewswire
Jul-06-21 10:19AM	Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B Benzinga
07:00AM	Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection GlobeNewswire
Jun-29-21 07:00AM	Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection GlobeNewswire -6.53%
Jun-28-21 06:55AM	Arbutus Biopharma Stock Jumps On Encouraging Data From Hepatitis B Candidate Benzinga
04:52AM	Premarket Movers Monday: Intellia Therapeutics, Boeing, Nvidia TheStreet.com
04:37AM	Arbutus Higher After Report of Progress With Hepatitis B Drug TheStreet.com
Jun-26-21 07:15AM	Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress 2021 - All Selected for Best of ILC GlobeNewswire
Jun-15-21 01:19AM	Here's Why We're Not Too Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation Simply Wall St. -6.47%
Jun-02-21 07:30AM	Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June GlobeNewswire

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sofia Michael J.	Chief Scientific Officer	Dec 01	Sale	5.09	200,000	1,018,000	1,303,403	Dec 03 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience